People · Operator
Named in public records as an officer, director or promoter · active 2016–2021 · Other Health Care, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Saranas Inc. | — | Other Health Care | Series B | $29.2M | $249.6M | 2016 |
| Nia Therapeutics, Inc. | — | Pharma | Series B | $21.4M | $357.4M | 2021 |
Milton Morris at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Milton Morris on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian R. Smith | 1 | 21 |
| Daniel Hawkins | 1 | 4 |
| Larry Lawson | 1 | 4 |
| James Reinstein | 1 | 3 |
| Milton M. Morris | 1 | 2 |
| John Huff | 1 | 2 |
| Jonathan Wachter | 1 | 1 |
| Daniil Utin | 1 | 1 |
| Daniel Rizzuto | 1 | 1 |
| Larry Greenberg | 1 | 1 |
| Michael Kahana | 1 | 1 |
| Dan Wolterman | 1 | 1 |
| Amy Kobe | 1 | 1 |
| Daniel R. Hawkins | 1 | 1 |
| Kevin Maples | 1 | 1 |
| Zaffer Syed | 1 | 1 |
| Maples Kevin | 1 | 1 |
| Gill M. Jack | 1 | 1 |
| Michael Magnani | 1 | 1 |
| Mehdi Razavi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.